Kit for detecting tumor-associated fibroblasts and M2-type tumor-associated macrophages and application thereof
By designing kits and full-spectrum fluorescence imaging systems that match targeted antibodies and fluorescent dyes, the defects of CAF and M2-TAM detection in the prior art are solved, and high-precision detection is achieved, avoiding section deslicing and antigen epitope The loss meets the high accuracy requirements of scientific research and clinical testing.
Patent Information
- Application Number
- CN202410301169.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-05
AI Technical Summary
Existing multiple fluorescence immunohistochemistry methods lack targeted methods for tumor-associated fibroblasts (CAF) and M2 tumor-associated macrophages (TAM)-related biomarkers, and the cyclic staining method based on tyramine signal amplification technology is used. Microwave antigen repair or high-temperature antigen repair can easily lead to tissue section desegment and heat loss of antigen epitope.
A kit was designed to combine tyramine signal amplification technology to match fluorescent dyes using specific antibodies and label biomarkers of multiple CAF and M2-TAM on the same tissue section through a full spectrum fluorescence imaging system and For imaging, use low-temperature antibody eluent instead of microwave repair to avoid section desegment problems.
It realizes high-precision and high-accuracy detection of multiple CAF and M2-TAM biomarkers on the same tissue section, meets the needs of scientific research and clinical testing, avoids sample waste and section deslicing problems, and reduces labor costs. .
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of immunohistochemistry, and in particular, relates to a kit for detecting tumor-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs) and an application thereof. Background Art
[0002] Immunohistochemistry (IHC) is a technique that uses the principle of specific binding between antigen and antibody to determine the location, qualitative and quantitative of antigens in tissue cells by chemical reaction to make the colorimetric agent of the labeled antibody develop color or by fluorescent colorimetric development. Due to its advantages such as strong specificity, high sensitivity, accurate positioning, combination of morphology and function, simplicity and rapidity, it has been widely used in life science, translational medicine research and clinical diagnosis, especially tumor diagnosis, for many years. With the continuous development of tumor biology research and the increasing research on tumor-targeted new drugs, the demand for the detection of tumor immune-related biomarkers is also increasing, and IHC, which can only detect a single marker, can no longer meet the demand. On the basis of traditional IHC, combined with tyramide signal amplification (TSA) technology, multiple biomarkers can be co-stained on the same tissue section through cyclic staining. While meeting the needs of traditional IHC for the qualitative and quantitative research of the location of a single biomarker, it can also study the co-localization, expression level and interaction between them.
[0003] The tumor microenvironment has been widely recognized to have an important influence on the occurrence, development, migration, and response to different tumor treatments of tumors. Tumor-associated fibroblasts (CAFs) are one of the most abundant and important components in the tumor microenvironment and are believed to promote tumor growth and development by establishing and remodeling the extracellular matrix. Studies have shown that CAFs are highly heterogeneous in different tissues and organs and in different individuals, and exhibit different biological functions. FAP, α-SMA, PDGFR, S100A4, etc. are widely studied CAF biomarkers, and the differential expression of biomarkers in CAFs exhibits different biological effects and has different effects on tumor development and tumor treatment [1]. Tumor-associated macrophages (TAMs) account for nearly 50% of human tumor tissues and are a highly heterogeneous cell population. Different subpopulations of cells exhibit different biological functions, which can support tumor growth and metastasis, as well as inhibit tumor development and metastasis. CD68 is the most important biomarker of TAM. According to the polarization status, TAM can be divided into M1-TAM (the main biomarkers are HLADR, CD80 / 86) and M2-TAM (the main biomarkers are CD206, CD163, CD204, stabilin-1). Among them, TAM is generally dominated by M2-TAM, which supports tumor growth by inhibiting the immune function of the tumor microenvironment and inducing angiogenesis [2-3]. In summary, CAF and M2-TAM biomarkers have become a hot topic in tumor research as biomarkers and therapeutic targets for tumor diagnosis and prognosis.
[0004] At present, there are methods for using TSA fluorescent dyes to perform multiple immunohistochemical detection of tumors. For example, Chinese patent application CN116008549A uses branched TSA dyes to replace DAB dyes in traditional IHC. Through multiple rounds of staining, up to 8 different antigens on the same tissue section can be fluorescently labeled differently. At the same time, combined with a full-spectrum fluorescence imaging system and spectral splitting imaging software, up to 9 colors (including cell nuclei) of tissue sections can be imaged. However, the microwave antigen repair method used multiple times in this scheme has the probability of causing tissue section detachment and antigen epitope heat loss [4], and does not consider the correspondence between antigen epitope abundance and fluorescent dye signal. For example, Chinese patent application CN111830256A uses TSA signal amplification technology. After the primary antibody binds to the antigen, the HRP-labeled secondary antibody is incubated. HRP catalyzes the addition of the fluorescent substrate to the system to generate an activated fluorescent substrate. The activated substrate can covalently bind to the tyrosine on the antigen, so that the sample is stably covalently bound to the fluorescent. After that, the non-covalently bound antibody is washed away by heat repair, and multiple labeling is achieved by repeated cycles. However, this scheme requires step-by-step staining, first catalyzing the linking of Biotin-Tyramide and then using Strepavidin-dye. The operation is complicated, the labor requirements are high, and the correspondence between the abundance of antigen epitopes and the fluorescent dye signal is not considered. Summary of the invention
[0005] The technical problem to be solved by the present invention is that the existing multiple fluorescent immunohistochemistry methods lack targeted methods for CAF and M2-TAM related biomarkers, and most of the cyclic staining methods based on tyramide signal amplification (TSA) technology use microwave antigen repair or high temperature antigen repair to elute antibodies, ignoring the defects of possible detachment, multiple high temperature antigen loss and other problems. The present invention provides a kit for detecting tumor-associated fibroblasts (CAF) and M2 tumor-associated macrophages (TAM) and its application. Based on tyramide signal amplification (TSA) technology, the kit can be used to mark multiple CAF and M2-TAM biomarkers in tumor tissue on the same tissue section, and the kit can be used on an automated staining instrument. By combining a full-spectrum fluorescence imaging system, the entire tissue section can be imaged and analyzed. The kit of the present invention is simple to use, low in labor cost, and highly repeatable, and can meet the requirements of high precision and high accuracy in scientific research and clinical testing.
[0006] The present invention designs the optimal match and incubation sequence of antibodies and fluorescent dyes according to the expression characteristics of the six biomarkers and the performance differences of different fluorescent pigments, and completes the analysis of the six biomarkers related to CAF and M2-TAM in the whole tissue section by combining with a full-spectrum fluorescence imaging system.
[0007] The present invention solves the above technical problems through the following technical solutions.
[0008] The first aspect of the present invention provides a kit for detecting tumor-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs), the kit comprising the following components: an antibody eluate, a primary antibody group and a multiplex fluorescent immunohistochemistry reagent group; the primary antibody group comprises 6 biomarkers: CD206, CD68, α-SMA, CD163, PDGFR and FAP; the multiplex fluorescent immunohistochemistry reagent group comprises a TSA fluorescent dye group corresponding one-to-one to the specific antibodies; the antibody eluate is used for elution after staining with the specific antibody.
[0009] In some embodiments, the TSA fluorescent dye set includes TSA480, TSA520, TSA570, TSA620, TSA690, TSA780 and DAPI.
[0010] In some embodiments, the TSA480 corresponds to CD206 antibody; the TSA520 corresponds to CD68 antibody; the TSA570 corresponds to α-SMA antibody; the TSA620 corresponds to CD163 antibody; the TSA690 corresponds to PDGFR antibody; and the TSA780 corresponds to FAP antibody.
[0011] In some specific embodiments, the CD206 antibody, PDGFR antibody and FAP antibody are purchased from Abcam with catalog numbers ab64693, ab69506 and ab53066, respectively; the CD68 antibody, α-SMA antibody and CD163 antibody are purchased from biolegend with catalog numbers 375602, 904601 and 364302, respectively.
[0012] In some embodiments, the antibody eluent is an antibody eluent with a working temperature of 37-50° C., such as an antibody eluent from IBIXIN with a product number of Abs994.
[0013] In some embodiments, the wash solution is TBS wash solution.
[0014] In some embodiments, the kit further comprises a signal amplification reaction solution, a pika-rabbit mixed HRP-labeled secondary antibody and a blocking solution.
[0015] In some embodiments, the kit further comprises a dewaxing solution, an antigen retrieval solution, a washing solution, a 3-5% hydrogen peroxide solution, an ethanol solution, and an anti-fluorescence quenching sealing medium.
[0016] In some embodiments, the hydrogen peroxide solution is a 3% hydrogen peroxide solution.
[0017] In some embodiments, the antigen retrieval solution is an alkaline antigen retrieval solution with a pH of 8.9-9.1.
[0018] In some embodiments, the alkaline antigen retrieval solution is an EDTA solution.
[0019] In some specific embodiments, the antigen retrieval solution is an EDTA solution with a pH value of 9.
[0020] The second aspect of the present invention provides a method for using a kit for detecting tumor-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs) in tumor detection, wherein the method uses the kit as described in the first aspect to perform primary antibody incubation and secondary antibody incubation and then staining on FFPE sections.
[0021] In some embodiments, the primary antibody incubation is performed in the order of anti-CD206, CD68, α-SMA, CD163, PDGFR, and FAP specific antibodies.
[0022] In some embodiments, the FFPE sections are tumor tissue sections.
[0023] In some embodiments, the secondary antibody used in the secondary antibody incubation is a mouse-rabbit mixed HRP-labeled secondary antibody.
[0024] In some embodiments, the FFPE sections are washed with a wash solution after incubation with the primary antibody and incubation with the secondary antibody and before staining.
[0025] In some embodiments, the FFPE slice is a FFPE slice that has been blocked; the blocking treatment is to incubate the FFPE slice with a 3-5% hydrogen peroxide solution and then place the slice in a blocking solution for incubation at room temperature.
[0026] In some embodiments, the blocked FFPE sections are subjected to antigen retrieval treatment before incubation in 3-5% hydrogen peroxide solution.
[0027] In some embodiments, the antigen retrieval treatment is to place the FFPE sections in an antigen retrieval solution at 98° C. and then rinse.
[0028] In some embodiments, the FFPE sections used for the antigen retrieval treatment are pre-treated sections, and the pre-treatment includes drying and dewaxing.
[0029] In some embodiments, the FFPE sections used for the antigen retrieval treatment are dewaxed FFPE sections.
[0030] In some embodiments, the method comprises the steps of:
[0031] Step 1: Place the slices in a 60°C constant temperature oven and bake for 3 hours to obtain dried slices;
[0032] Step 2: Dewax the dried slices in a 72°C dewaxing solution for 1 minute, rinse them with an ethanol solution for 3 times, and rinse them with a washing solution for 3 times to obtain pretreated slices;
[0033] Step 3: Place the pretreated slices in an antigen repair solution at 98°C for 20 minutes, and wash them with a washing solution for 5 times to obtain the repaired slices;
[0034] Step 4: Incubate the repaired slices in a 3% hydrogen peroxide solution at room temperature for 15 minutes, and rinse them three times with a washing solution to obtain slices treated with hydrogen peroxide;
[0035] Step 5: Incubate the hydrogen peroxide-treated slices in a blocking solution at room temperature for 15 minutes to obtain blocked slices;
[0036] Step 6: Incubate the blocked sections with the primary antibody solution at 37°C for 1 hour, and wash them 4 times with the washing solution to obtain the sections incubated with the primary antibody;
[0037] Step 7: Incubate the sections after primary antibody incubation with pika-rabbit mixed HRP-labeled secondary antibody at room temperature for 15-30 minutes, and wash with washing solution 4 times to obtain sections after secondary antibody incubation;
[0038] Step 8: Incubate the sections after incubation with the secondary antibody with TSA fluorescent dye at room temperature for 15-30 minutes, and wash them with washing solution 4 times to obtain stained sections;
[0039] Step 9: Incubate the stained sections in the antibody elution solution preheated at 37°C for 20 minutes and wash them three times with the washing solution;
[0040] Step 10: after repeating steps 5 to 9 four times, repeating steps 5 to 8 once, so that the six biomarkers are respectively labeled to obtain six stained sections;
[0041] Step 11: Incubate the sections stained 6 times with DAPI at room temperature for 5-20 minutes, wash them 3 times with washing solution, and wash them 3 times with sterile water to obtain sections that have been stained;
[0042] Step 12: The stained slices are sealed with an anti-fluorescence quenching sealing agent to obtain sealed slices.
[0043] Step 13: Use a full-spectrum fluorescence imaging system to photograph the slices after sealing, and obtain images of the corresponding fluorescence channels of each biomarker in the whole tissue slice and a merged fluorescence image.
[0044] In some embodiments, the primary antibodies are incubated with the primary antibodies described in step 6 in the order of CD206, CD68, α-SMA, CD163, PDGFR, and FAP.
[0045] In some specific embodiments, the TSA fluorescent dye is incubated with the TSA fluorescent dye described in step 8 in the order of TSA480, TSA520, TSA570, TSA620, TSA690, and TSA780.
[0046] In some specific embodiments, the correspondence between the primary antibody and the fluorescent dye is CD206 corresponds to TSA480, CD68 corresponds to TSA520, α-SMA corresponds to TSA570, CD163 corresponds to TSA620, PDGFR corresponds to TSA690, and FAP corresponds to TSA780.
[0047] In some embodiments, imaging is performed using the Akoya Vectra Polaris full-spectrum fluorescence imaging system to obtain full-spectrum fluorescence images of six biomarkers.
[0048] The third aspect of the present invention provides a use of the kit as described in the first aspect in detecting tumor-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs).
[0049] In some embodiments, the detection is for non-diagnostic purposes, for example, to evaluate the content of CAF and M2-TAM in FFPE sections to determine whether the FFPE sections meet the preparation or detection standards for drug screening.
[0050] Beneficial effects achieved by the present invention:
[0051] The kit of the present invention not only has the advantages of high specificity, high sensitivity and accurate positioning of traditional IHC technology, but also (1) achieves the labeling of multiple CAF and M2-TAM biomarkers in tumor tissue on the same tissue section based on tyramide signal amplification (TSA) technology, thereby avoiding sample waste and analyzing the co-localization expression, spatial position and grouping of biomarkers; and (2) uses low-temperature antibody elution solution to elute antibodies during the staining process instead of the microwave repair process, thereby avoiding the problem of section detachment that may be caused by multiple microwave antigen repairs.
[0052] The kit of the present invention is easy to use, has low labor cost, and is highly repeatable, and avoids the problem of slicing off that may be caused by multiple microwave antigen repairs, and fully meets the requirements of high precision and high accuracy for scientific research and clinical testing. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1It is the whole tissue area fluorescence image of the co-expression of the 6 biomarkers provided in the example (scale bar is 2 mm).
[0054] Figure 2 It is a fluorescence image of the local tissue area of the co-expression of the six biomarkers provided in the example (the scale bar is 50 μm).
[0055] Figure 3 It is a fluorescence image of the biomarker CD206 provided in the examples at 480 nm fluorescence channel (scale bar is 50 μm).
[0056] Figure 4 It is a fluorescence image of the biomarker CD68 provided in the examples at 520 nm fluorescence channel (scale bar is 50 μm).
[0057] Figure 5 It is a fluorescence image of the biomarker α-SMA provided in the examples at 570 nm fluorescence channel (scale bar is 50 μm).
[0058] Figure 6 It is a fluorescence image of the biomarker CD163 provided in the examples at 620 nm fluorescence channel (scale bar is 50 μm).
[0059] Figure 7 It is a fluorescence image of the biomarker PDGFR provided in the examples at 690 nm fluorescence channel (scale bar is 50 μm).
[0060] Figure 8 It is a fluorescence image of the biomarker FAP provided in the examples at 780 nm fluorescence channel (scale bar is 50 μm).
[0061] Fig. 9 It is the whole tissue area fluorescence image of the co-expression of 6 biomarkers provided in the comparative example (scale bar is 2 mm).
[0062] Fig.10 It is the fluorescence image of the local tissue area of the co-expression of the six biomarkers provided in the comparative example (the scale bar is 50 μm). DETAILED DESCRIPTION
[0063] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0064] To further explain the content of the present invention, the present invention will be described in detail in combination with the following examples and comparative examples. The FFPE samples used were purchased from Shanghai Xinchao Biotechnology Co., Ltd.
[0065] Example
[0066] This embodiment is a method for using a kit for detecting tumor-associated fibroblasts (CAFs) and M2 tumor-associated macrophages (TAMs) that can be used on an automated staining instrument, and the slices used are human triple-negative breast cancer FFPE samples. The specific operations of the embodiment are as follows:
[0067] The reagents used in the examples are shown in Table 1:
[0068] Table 1. Reagent information
[0069]
[0070]
[0071] The instruments and equipment used in the examples are shown in Table 2:
[0072] Table 2. Instrument information
[0073] instrument Automated staining platform Leica Bond Rx Akoya Vectra Polaris Full Spectrum Fluorescence Imaging System factory Lecia Akoya
[0074] The operation steps in the embodiment are as follows:
[0075] 1. Baking sheet:
[0076] Insert the slices into the slice rack, place in a 60°C oven, take them out after 3 hours ± 10 minutes, and cool to room temperature.
[0077] 2. Solution preparation:
[0078] Prepare the primary antibody solution. Fluorescent dyes were diluted with signal amplification reaction solution according to the manufacturer's instructions. DAPI was diluted with sterile water according to the manufacturer's instructions. The dilution ratio of the primary antibody and the corresponding dye are shown in Table 3:
[0079] Table 3. Primary antibody solution preparation
[0080]
[0081] 3. Staining of sections:
[0082] The automatic staining platform Leica Bond Rx was used for dewaxing, antigen repair and multiple rounds of staining. After the sections were loaded into the instrument, the dewaxing program (see Table 4), antigen repair program (see Table 5), and staining program (see Table 6) were run in sequence.
[0083] Table 4. Deparaffinization procedures
[0084]
[0085]
[0086] Table 5. Antigen retrieval procedures
[0087]
[0088]
[0089] Table 6. Staining procedures
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105] 4. Sealing film:
[0106] Add an appropriate amount of anti-fluorescence quenching mounting medium on the tissue, cover the tissue with a coverslip of appropriate size, ensure that the tissue is evenly covered and the coverslip is flat on the tissue, and place the sealed slices flat in a fume hood to dry.
[0107] 5. Scanning imaging:
[0108] The sections were mounted on the Akoya Vectra Polaris full-spectrum fluorescence imaging system for imaging.
[0109] Figure 1 This is the fluorescence image of the whole tissue area where 6 biomarkers are co-expressed. Figure 2 This is the fluorescence image of the local tissue area where six biomarkers are co-expressed. Figure 3 This is the fluorescence image of the biomarker CD206 at 480nm fluorescence channel. Figure 4 This is the fluorescence image of the biomarker CD68 at 520nm fluorescence channel. Figure 5 This is the fluorescence image of the biomarker α-SMA in the 570nm fluorescence channel. Figure 6 This is the fluorescence image of the biomarker CD163 at 620nm fluorescence channel. Figure 7 This is the fluorescence image of the biomarker PDGFR at 690nm fluorescence channel. Figure 8 This is the fluorescence image of the biomarker FAP in the 780nm fluorescence channel.
[0110] The above-described embodiments merely express preferred implementation modes of the present invention. The steps in the embodiments are relatively detailed, but should not be considered as limiting the patent scope of the present invention.
[0111] In the present invention, the antibody incubation sequence, the fluorescent dye incubation sequence, and the corresponding relationship between the antibody and the fluorescent dye cannot be changed at will.
[0112] This embodiment uses a fully automatic staining instrument for operation, but it should not be considered that the patent scope of the present invention only includes the use on the fully automatic staining instrument. For technicians in this field, without departing from the content of the claims of this patent, making several substitutions all fall within the scope of protection of the present invention.
[0113] Comparative Example
[0114] This comparative example refers to the method of multiple rounds of high-temperature microwave elution of antibodies in the published patent application "A multiple fluorescent immunohistochemical detection kit and its application" (CN116008549A), and uses multiple rounds of high-temperature repair and elution of antibodies for multiple fluorescent immunohistochemical detection. The slices used are human triple-negative breast cancer FFPE samples. The specific operations of the comparative example are as follows:
[0115] The reagents used in the comparative example are shown in Table 7:
[0116] Table 7. Reagent information
[0117]
[0118]
[0119] The instruments and equipment used in the comparative example are shown in Table 2.
[0120] The operation steps in the comparative example are as follows:
[0121] 1. Baking sheet:
[0122] Insert the slices into the slice rack, place in a 60°C oven, take them out after 1 hour ± 10 minutes, and cool to room temperature.
[0123] 2. Solution preparation:
[0124] Prepare the primary antibody solution. Fluorescent dyes were diluted with signal amplification reaction solution according to the manufacturer's instructions. DAPI was diluted with sterile water according to the manufacturer's instructions. The dilution ratio of the primary antibody and the corresponding dye are shown in Table 3:
[0125] Table 8. Primary antibody solution preparation
[0126]
[0127] 3. Staining of sections:
[0128] The automatic staining platform Leica Bond Rx was used for dewaxing, antigen repair and multiple rounds of staining. After the sections were loaded into the instrument, the dewaxing program (see Table 4), antigen repair program (see Table 5), and staining program (see Table 9) were run in sequence.
[0129] Table 9. Staining procedures
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145] 4. Sealing film:
[0146] Add an appropriate amount of anti-fluorescence quenching mounting medium on the tissue, cover the tissue with a coverslip of appropriate size, ensure that the tissue is evenly covered and the coverslip is flat on the tissue, and place the sealed slices flat in a fume hood to dry.
[0147] 5. Scanning imaging:
[0148] The sections were mounted on the Akoya Vectra Polaris full-spectrum fluorescence imaging system for imaging.
[0149] Fig. 9 This is the fluorescence image of the whole tissue area where 6 markers are co-expressed. Fig.10 This is the fluorescence image of the local tissue area where six biomarkers are co-expressed. Fig. 9 The tissue fragment in the upper left corner shows that the tissue sample is severely delaminated. Fig.10 The detailed image shown demonstrates the adverse effect of overlapping folds caused by tissue shedding on the results.
[0150] References
[0151] [1]Han, C., Liu, T. & Yin, R. Biomarkers for cancer-associated fibroblasts. Biomark Res 8, 64 (2020).
[0152] [2]Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application[J]. Journal of hematology&oncology, 2017, 10(1):1-12.
[0153] [3]Larionova I,Tuguzbaeva G,Ponomaryova A,et al.Tumor-associatedmacrophages in human breast,colorectal,lung,ovarian and prostate cancers[J].Frontiers in oncology,2020,10:566511.[4]Pang L,Ernst M,Huynh J.Developmentof a Multiplex Immunohistochemistry Workflow to Investigate the ImmuneMicroenvironment in Mouse Models of Inflammatory Bowel Disease and ColonCancer.Int J Mol Sci.2021Oct 12;22(20):11001.doi:10.3390 / ijms222011001.PMID:34681666;PMCID:PMC8539370。
Claims
1. A kit for detecting tumor-associated fibroblasts and M2 tumor-associated macrophages, characterized in that: The kit includes the following components: antibody eluate, a primary antibody group and a multiplex fluorescent immunohistochemistry reagent group; the primary antibody group includes specific antibodies for 6 biomarkers: CD206, CD68, α-SMA, CD163, PDGFR and FAP; The multiple fluorescent immunohistochemistry reagent set includes a TSA fluorescent dye set corresponding to the specific antibodies one by one; The antibody elution solution is used for elution after staining with the specific antibody.
2. The kit according to claim 1, characterized in that: The TSA fluorescent dye group includes TSA480, TSA520, TSA570, TSA620, TSA690, TSA780 and DAPI; The TSA480 corresponds to the CD206 antibody; the TSA520 corresponds to the CD68 antibody; the TSA570 corresponds to the α-SMA antibody; the TSA620 corresponds to the CD163 antibody; the TSA690 corresponds to the PDGFR antibody; and the TSA780 corresponds to the FAP antibody.
3. The kit according to claim 1 or 2, characterized in that The multiplex fluorescent immunohistochemistry reagent set also includes a signal amplification reaction solution, a pika-rabbit mixed HRP-labeled secondary antibody and a blocking solution; And / or, the antibody eluent is an antibody eluent with a working temperature of 37-50° C., preferably an antibody eluent of Abs994 from IBC; and / or, the washing solution is TBS washing solution.
4. The kit according to any one of claims 1 to 3, characterized in that: The kit also includes a dewaxing solution, an antigen repair solution, a washing solution, a 3-5% hydrogen peroxide solution, an ethanol solution and an anti-fluorescence quenching sealing medium.
5. The kit according to any one of claims 1 to 4, characterized in that: The antigen repair solution is an alkaline antigen repair solution with a pH value of 8.9-9.1; preferably, the alkaline antigen repair solution is an EDTA solution.
6. A method for detecting tumor-associated fibroblasts and M2 tumor-associated macrophages, characterized in that: The method uses the kit according to any one of claims 1 to 5 to perform primary antibody incubation and secondary antibody incubation and post-staining on FFPE sections; Preferably, the primary antibody incubation is carried out in the order of anti-CD206, CD68, α-SMA, CD163, PDGFR, and FAP specific antibodies.
7. The method according to claim 6, characterized in that The secondary antibody used in the secondary antibody incubation is a pika-rabbit mixed HRP-labeled secondary antibody; And / or, the FFPE sections are washed with a washing solution after incubation with the primary antibody and the secondary antibody and before staining; And / or, the FFPE slices are FFPE slices that have been subjected to a blocking treatment; the blocking treatment is to incubate the FFPE slices with a 3-5% hydrogen peroxide solution and then place the slices in a blocking solution for incubation at room temperature.
8. The method according to claim 7, characterized in that The sealed FFPE sections are subjected to antigen repair treatment before incubation in a 3-5% hydrogen peroxide solution; the antigen repair treatment is preferably performed by placing the FFPE sections in an antigen repair solution and then rinsing them at 98°C; Preferably, the FFPE sections used for the antigen repair treatment are pre-treated sections, and the pre-treatment is preferably drying and dewaxing, or the FFPE sections used for the antigen repair treatment are dewaxed FFPE sections.
9. The method according to any one of claims 6 to 8, characterized in that: The method comprises the following steps: Step 1: Place the slices in a 60°C constant temperature oven and bake for 3 hours to obtain dried slices; Step 2: Dewax the dried slices at 72°C for 1 minute, rinse them 3 times with ethanol solution, and rinse them 3 times with washing solution to obtain pretreated slices; Step 3: Place the pretreated slices in an antigen repair solution at 98°C for 20 minutes, and wash them with a washing solution for 5 times to obtain the repaired slices; Step 4: Incubate the repaired slices in a 3% hydrogen peroxide solution at room temperature for 15 minutes, and rinse them three times with a washing solution to obtain slices treated with hydrogen peroxide; Step 5: Incubate the hydrogen peroxide-treated slices in a blocking solution at room temperature for 15 minutes to obtain blocked slices; Step 6: Incubate the blocked sections with the primary antibody solution at 37°C for 1 hour, and wash them 4 times with the washing solution to obtain the sections incubated with the primary antibody; Step 7: Incubate the sections after primary antibody incubation with pika-rabbit mixed HRP-labeled secondary antibody at room temperature for 15-30 minutes, and wash with washing solution 4 times to obtain sections after secondary antibody incubation; Step 8: Incubate the sections after secondary antibody incubation with TSA fluorescent dye at room temperature for 15-30 minutes, and wash them with washing solution 4 times to obtain stained sections; Step 9: Incubate the stained sections in the antibody elution solution preheated at 37°C for 20 minutes and wash them three times with the washing solution; Step 10: after repeating steps 5 to 9 for 4 times, repeating steps 5 to 8 once, so that the 6 biomarkers are respectively labeled to obtain 6 stained sections; Step 11: Incubate the sections stained 6 times with DAPI at room temperature for 5-20 minutes, wash them 3 times with washing solution, and wash them 3 times with sterile water to obtain sections that have been stained; Step 12: The stained slices are sealed with an anti-fluorescence quenching sealing agent to obtain sealed slices; Step 13: Use a full-spectrum fluorescence imaging system to photograph the slices after sealing, and obtain images of the corresponding fluorescence channels of each biomarker in the whole tissue slice and a merged fluorescence image.
10. Use of the kit according to any one of claims 1 to 5 in detecting tumor-associated fibroblasts and M2 tumor-associated macrophages.
Citation Information
Cited By
Method for detecting Breg cells and Tfh cells in thymoma tissue microenvironment
CN119290546A
TUNEL-TSA multiple fluorescent staining method based on TSA technology optimization and application of TUNEL-TSA multiple fluorescent staining method
CN120177788A
